南京科佰生物科技有限公司官方网站欢迎您的光临!

免费咨询热线: 4008-750-250

搜索
确认
取消
/
/
/
/
KIF5B(E15)-RET(E12) [V804M]/BaF3

科研细胞

科研细胞

药靶细胞

药靶细胞

标准品

标准品
浏览量:
0

KIF5B(E15)-RET(E12) [V804M]/BaF3

所属分类
返回列表
1
零售价
0.0
市场价
0.0
浏览量:
0
产品编号
CBP73196
货号:
CBP73196
品牌:
Cobioer
规格:
T-25 Flask
物种:
组织:
数量
-
+
库存:
0
产品描述
参数
产品数据库
CBP73196
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804M]/BaF3

Host Cell:

BA/F3

Stability: 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative

 
II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.

 
III. Representative Data

1. WB of  KIF5B-RET [V804M]/BaF3

2. Sanger of KIF5B-RET [V804M]/BaF3

3. Anti-proliferation assay

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret(S) V804M Cells (C1).

未找到相应参数组,请于后台属性模板中添加

相关文件

  • Manual download:CBP73196 KIF5B-RET [V804M] BaF3.pdf

    大小:
    2022-08-02
上一页
1

相关产品推荐

暂时没有内容信息显示
请先在网站后台添加数据记录。

联系我们

地址:南京市雨花台区长虹路222号/实验室地址:上海市浦东新区广丹路222号 

邮箱: sales@cobioer.com (销售部) tech@cobioer.com (技术部)

 COBIOER

扫一扫,关注我们公众号

Copyright ©2021 www.cobioer.com All Rights Reserved. 南京科佰生物科技有限公司版权所有 苏ICP备13038923号